Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Time to Sell?

Key Points

• Dyne Therapeutics shares fell 20.9%, opening at $17.08 versus a prior close of $24.28, before trading near $18.69 on heavy volume.
• The company reported a quarterly loss of $1.08 per share, missing the $0.75 analyst estimate; analysts expect a full-year loss of approximately $3.47 per share.
• Despite the selloff, analysts maintain a “Moderate Buy” consensus with a $34.42 price target, while insiders sold roughly $99.4 million of stock over the past three months.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s share price gapped down prior to trading on Tuesday . The stock had previously closed at $24.28, but opened at $17.08. Dyne Therapeutics shares last traded at $18.69, with a volume of 2,729,682 shares changing hands.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. TD Cowen assumed coverage on Dyne Therapeutics in a report on Friday, June 26th. They set a "buy" rating on the stock. HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Monday, August 17th. Wall Street Zen cut Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 1st. Royal Bank Of Canada increased their price target on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a report on Thursday, July 30th. Finally, Morgan Stanley reduced their price objective on shares of Dyne Therapeutics from $47.00 to $45.00 and set an "overweight" rating for the company in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.42.

Dyne Therapeutics Stock Down 20.9%

The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The company has a market cap of $3.59 billion, a PE ratio of -5.72 and a beta of 1.08. The company has a fifty day moving average price of $24.86 and a 200 day moving average price of $20.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, analysts anticipate that Dyne Therapeutics, Inc. will post -3.47 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Erick Lucera sold 2,362 shares of Dyne Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total transaction of $48,113.94. Following the completion of the sale, the chief financial officer directly owned 121,563 shares of the company's stock, valued at approximately $2,476,238.31. The trade was a 1.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jason P. Rhodes sold 2,160,516 shares of the company's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the transaction, the director owned 428,946 shares of the company's stock, valued at $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,139,196 shares of company stock worth $99,449,852 in the last three months. Insiders own 9.46% of the company's stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC bought a new position in shares of Dyne Therapeutics during the 1st quarter valued at about $26,000. Strs Ohio purchased a new position in shares of Dyne Therapeutics during the 4th quarter valued at about $51,000. Allworth Financial LP bought a new stake in Dyne Therapeutics in the 2nd quarter worth approximately $62,000. Aster Capital Management DIFC Ltd bought a new stake in Dyne Therapeutics in the 4th quarter worth approximately $84,000. Finally, Steward Partners Investment Advisory LLC boosted its stake in Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company's stock worth $95,000 after buying an additional 2,465 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.